FDA moves to limit compounding of GLP-1s

The FDA proposed Thursday not adding three active ingredients in weight-loss drugs to its so-called bulks list.
Medscape

FDA Proposes End to Mass GLP-1 Compounding

The US FDA has proposed an end to most types of compounding of semaglutide, tirzepatide, and liraglutide. The agency said in a statement it has determined there is no longer a clinical need for ...
National Law Review

FDA Signals it Has No Appetite to Add Popular GLP-1 Drug Substances to the 503B Bulks List

Key Takeaways FDA has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. The proposal would materially limit 503B bulk compounding of these GLP-1 products. Comments ...
Becker's Hospital Review

FDA seeks to restrict compounding of key GLP-1s

FDA seeks restrict compounding of GLP-1 drugs by excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list to limit unauthorized use.
MedPage Today on MSN

FDA Intensifies Crackdown on GLP-1 Compounding

Agency proposal would exclude semaglutide, tirzepatide, and liraglutide from 503B bulks li ...
RAPS

FDA Warns California Drug Distributor for Listing Deficiencies

The US Food and Drug Administration (FDA) on Tuesday released a warning letter sent to Orange, CA-based distributor NuCare Pharmaceuticals after the company failed to correct certain drug ...
Becker's Hospital Review

FDA clears Walgreens in drug listing violations case

The FDA said Walgreens has addressed violations related to drug listing deficiencies for one of its products, according to a Dec. 19 close-out letter. The agency previously cited Walgreens in ...